Mark C Genovese
Overview
Explore the profile of Mark C Genovese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
167
Citations
7593
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westhovens R, Winthrop K, Kavanaugh A, Greenwald M, Dagna L, Cseuz R, et al.
RMD Open
. 2025 Jan;
11(1).
PMID: 39884731
Objectives: DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) trials. Methods: Eligible patients...
2.
Vermeire S, Schreiber S, Rubin D, DHaens G, Reinisch W, Watanabe M, et al.
Lancet Gastroenterol Hepatol
. 2024 Dec;
10(2):138-153.
PMID: 39637881
Background: There is a need for efficacious therapies for patients with Crohn's disease that are better tolerated and more durable than available treatments. We aimed to evaluate the efficacy and...
3.
Srivastava S, Watkins T, Nguyen Q, Sharma S, Scales D, Dacey M, et al.
JAMA Ophthalmol
. 2024 Jul;
142(9):789-797.
PMID: 39023880
Importance: Noninfectious uveitis is a leading cause of visual impairment with an unmet need for additional treatment options. Objective: To assess the efficacy and safety of filgotinib, a Janus kinase...
4.
Marsal S, Corominas H, de Agustin J, Perez-Garcia C, Lopez-Lasanta M, Borrell H, et al.
Lancet Rheumatol
. 2024 Jan;
3(4):e262-e269.
PMID: 38279410
Background: Vagus nerve stimulation delivered with an implanted device has been shown to improve rheumatoid arthritis severity. We aimed to investigate the safety and efficacy of non-invasive stimulation of the...
5.
Genovese M, Buckley C, Saurigny D, Schett G, Davy K, Gupta A, et al.
Lancet Rheumatol
. 2024 Jan;
3(7):e473-e474.
PMID: 38279397
No abstract available.
6.
Genovese M, Berkowitz M, Conaghan P, Peterfy C, Davy K, Fisheleva E, et al.
Lancet Rheumatol
. 2024 Jan;
2(11):e666-e676.
PMID: 38279363
Background: Otilimab is a human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), a driver in many immune-mediated inflammatory conditions. We evaluated the effect of otilimab on the GM-CSF-chemokine (C-C...
7.
Genovese M, Levine Y, Chernoff D
Lancet Rheumatol
. 2024 Jan;
3(1):e14-e15.
PMID: 38273635
No abstract available.
8.
Genovese M, Gaylis N, Sikes D, Kivitz A, Horowitz D, Peterfy C, et al.
Lancet Rheumatol
. 2024 Jan;
2(9):e527-e538.
PMID: 38273617
Methods: Participants with moderately to severely active rheumatoid arthritis and prior insufficient response to two or more biological disease-modifying anti-rheumatic drugs or Janus kinase inhibitors with at least two different...
9.
Genovese M, Smolen J, Takeuchi T, Burmester G, Brinker D, Rooney T, et al.
Lancet Rheumatol
. 2024 Jan;
2(6):e347-e357.
PMID: 38273598
Background: Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2, approved for the treatment of patients with active rheumatoid arthritis. Because baricitinib, like other disease-modifying antirheumatic...
10.
Baker M, Genovese M, Alataris K
Arthritis Rheumatol
. 2023 Oct;
PMID: 37899493
No abstract available.